We are live on ! Find out more
KPRX icon

Kiora Pharmaceuticals
KPRX

15 hedge funds and large institutions have $160K invested in Kiora Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 1

74% more capital invested

Capital invested by funds: $91.9K → $160K (+$67.6K)

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

15% more funds holding

Funds holding: 13 → 15 (+2)

0.19% more ownership

Funds ownership: 0.25% → 0.44% (+0.19%)

Holders
15
Holders Change
+2
Holders Change %
+15.38%
% of All Funds
0.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
3
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$53.4K
2
VF
Virtu Financial
New York
+$16.4K
3
Renaissance Technologies
Renaissance Technologies
New York
+$10.8K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$8.12K
5
UBS Group
UBS Group
Switzerland
+$431

Top Sellers

Rank Fund Capital Flow
1
XT
XTX Topco
Cayman Islands
-$6.94K
2
Wells Fargo
Wells Fargo
California
-$31
3
TRCT
Tower Research Capital (TRC)
New York
-$5
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$1
Name Holding Trade Value Shares
Change 		Change in
Stake
Citadel Advisors
1
Citadel Advisors
Florida
$49.1K +$53.4K +10,287 New
CAPTRUST Financial Advisors
2
CAPTRUST Financial Advisors
North Carolina
$41.8K – – –
Geode Capital Management
3
Geode Capital Management
Massachusetts
$19.7K – – –
VF
4
Virtu Financial
New York
$15K +$16.4K +3,160 New
Vanguard Group
5
Vanguard Group
Pennsylvania
$12.8K +$8.12K +1,563 +134%
Renaissance Technologies
6
Renaissance Technologies
New York
$10K +$10.8K +2,078 New
BlackRock
7
BlackRock
New York
$7.55K – – –
TRCT
8
Tower Research Capital (TRC)
New York
$2.18K -$5 -1 -0.2%
UBS Group
9
UBS Group
Switzerland
$1.15K +$431 +83 +51%
NA
10
NewEdge Advisors
Louisiana
$104 – – –
US Bancorp
11
US Bancorp
Minnesota
$35 – – –
Wells Fargo
12
Wells Fargo
California
$31 -$31 -6 -46%
Osaic Holdings
13
Osaic Holdings
Arizona
$19 – – –
Morgan Stanley
14
Morgan Stanley
New York
$8 +$5 +1 +100%
AFG
15
Albion Financial Group
Utah
$4 – – –
XT
16
XTX Topco
Cayman Islands
– -$6.94K -1,310 Closed
Fidelity Investments
17
Fidelity Investments
Massachusetts
– -$1 – –

KPRX Hedge Fund Activity: Q4 2023 in Review

15 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Kiora Pharmaceuticals (KPRX) for Q4 2023, worth a combined $160K — up 74% from $91.9K a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new KPRX positions and 1 closed out — a net gain of 2 holders — while 3 added to existing stakes and 2 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $53.4K. The largest seller was XTX Topco, exiting entirely with an estimated $6.94K sold.

  • 15 institutional investors held Kiora Pharmaceuticals (KPRX) as of Q4 2023, up from 13 in Q3 2023.
  • Funds reported $160K of Kiora Pharmaceuticals stock for Q4 2023, up 74% quarter-over-quarter.
  • 3 funds opened new Kiora Pharmaceuticals positions in Q4 2023 and 1 closed out, a net change of +2 holders.
  • The largest Kiora Pharmaceuticals buyer in Q4 2023 was Citadel Advisors, an estimated $53.4K added.
  • The largest Kiora Pharmaceuticals seller in Q4 2023 was XTX Topco, an estimated $6.94K sold.

Based on aggregated 13F filings for Q4 2023.